Patents by Inventor John ÖHD

John ÖHD has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SEVUPARIN FOR THE TREATMENT OF CHRONIC KIDNEY DISEASE
    Publication number: 20260216232
    Abstract: The present invention is directed to the substance sevuparin or a pharmaceutically acceptable salt thereof, for use in the treatment of a subject having a chronic kidney disease (CKD) which may also comprise anemia. This therapy may also be useful as combination therapy with standard of care (SOC) therapy, such as combination therapy with an erythropoiesis-stimulating agent (ESA) or with a HIF prolyl hydroxylase inhibitor agent.
    Type: Application
    Filed: December 20, 2023
    Publication date: July 30, 2026
    Inventors: John Öhd, Maura Poli
  • Sorafenib or regorafenib troxacitabine phosphoramidate prodrug combination therapy for liver cancer
    Patent number: 10960017
    Abstract: Combination therapy with sorafenib or regorafenib and a phosphoramidate prodrug of troxacitabine with the formula: where Y is C1-C8 straight or branched chain alkyl, X is H, halo, C3-C4cycloalkyl or C1-C4alkyl and Z is H or fluoro, or a pharmaceutically acceptable salt thereof, shows surprising utility in the treatment of liver cancer or liver metastasis.
    Type: Grant
    Filed: August 30, 2019
    Date of Patent: March 30, 2021
    Assignee: Medivir Aktiebolag
    Inventors: Mark Albertella, Anders Eneroth, Björn Klasson, Fredrik Öberg, John Öhd
  • SORAFENIB OR REGORAFENIB TROXACITABINE PHOSPHORAMIDATE PRODRUG COMBINATION THERAPY FOR LIVER CANCER
    Publication number: 20200009166
    Abstract: Combination therapy with sorafenib or regorafenib and a phosphoramidate prodrug of troxacitabine with the formula: where Y is C1-C8 straight or branched chain alkyl, X is H, halo, C3-C4cycloalkyl or C1-C4alkyl and Z is H or fluoro, or a pharmaceutically acceptable salt thereof, shows surprising utility in the treatment of liver cancer or liver metastasis.
    Type: Application
    Filed: August 30, 2019
    Publication date: January 9, 2020
    Applicant: Medivir Aktiebolag
    Inventors: Mark Albertella, Anders Eneroth, Björn Klasson, Fredrik Öberg, John Öhd
  • Combination therapy with sorafenib or regorafenib and a phosphoramidate prodrug of troxacitabine
    Patent number: 10456413
    Abstract: Combination therapy with sorafenib or regorafenib and a phosphoramidate prodrug of troxacitabine with the formula: where Y is C1-C8 straight or branched chain alkyl, X is H, halo, C3-C4cycloalkyl or C1-C4alkyl and Z is H or fluoro, or a pharmaceutically acceptable salt thereof, shows surprising utility in the treatment of liver cancer or liver metastasis.
    Type: Grant
    Filed: February 28, 2017
    Date of Patent: October 29, 2019
    Assignee: Medivir Aktiebolag
    Inventors: Mark Albertella, Anders Eneroth, Björn Klasson, Fredrik Öberg, John Öhd
  • COMBINATION THERAPY WITH SORAFENIB OR REGORAFENIB AND A PHOSPHORAMIDATE PRODRUG OF TROXACITABINE
    Publication number: 20190091246
    Abstract: Combination therapy with sorafenib or regorafenib and a phosphoramidate prodrug of troxacitabine with the formula: where Y is C1-C8 straight or branched chain alkyl, X is H, halo, C3-C4cycloalkyl or C1-C4alkyl and Z is H or fluoro, or a pharmaceutically acceptable salt thereof, shows surprising utility in the treatment of liver cancer or liver metastasis.
    Type: Application
    Filed: February 28, 2017
    Publication date: March 28, 2019
    Applicant: Medivir Aktiebolag
    Inventors: Mark ALBERTELLA, Anders ENEROTH, Björn KLASSON, Fredrik ÖBERG, John ÖHD